Instalab

Vanillylmandelic Acid (VMA)

Urine Test
Check whether a hidden catecholamine-producing tumor is driving unexplained spells of high blood pressure, sweating, or palpitations.

Should you take a Vanillylmandelic Acid (VMA) test?

This test is most useful if any of these apply to you.

Having Unexplained Blood Pressure Spells
If your blood pressure surges in episodes with sweating, palpitations, or headaches, this test can help reveal whether stress hormones are driving them.
Struggling With Treatment-Resistant Hypertension
If your blood pressure stays high despite multiple medications, this test can help rule out a hidden catecholamine-producing tumor as the cause.
Tracking Sympathetic Stress Load
If you suspect chronic stress or environmental exposures are pushing your nervous system into overdrive, this test gives an objective read on catecholamine output.
Monitored for a Catecholamine Tumor
If you have been diagnosed with or treated for pheochromocytoma, paraganglioma, or neuroblastoma, serial testing helps confirm the tumor stays away.

About Vanillylmandelic Acid (VMA)

If you have unexplained episodes of pounding heartbeat, sweating, headaches, or blood pressure spikes that come and go, the cause may not show up on a standard physical or routine lab panel. A urine test for VMA (vanillylmandelic acid) looks for chemical evidence that your adrenal glands or nerve tissue are pumping out unusually high amounts of stress hormones, sometimes from a small, treatable tumor that has been hiding for years.

VMA is a long-used marker for catecholamine-secreting tumors like pheochromocytoma, and it also gives a window into your overall sympathetic (fight-or-flight) nervous system activity. It is not a routine wellness number to chase week to week. It is a targeted question: are stress chemicals in your body running higher than they should?

What VMA Actually Is

Your adrenal glands (small organs on top of your kidneys) and your sympathetic nerve endings produce two stress chemicals: adrenaline (epinephrine) and noradrenaline (norepinephrine). After these chemicals do their job, your liver processes them into smaller breakdown products. VMA is one of those final products, and it exits the body in urine.

Because most of the adrenaline and noradrenaline your body makes ends up as VMA in urine, this single measurement reflects the overall pace of your stress-hormone production. The more catecholamines your tissues are pumping out, the more VMA your kidneys excrete.

Catecholamine-Secreting Tumors

The biggest reason to know your VMA level is to detect tumors that produce catecholamines on their own, independent of normal nervous system control. These tumors can cause severe, episodic high blood pressure and serious cardiovascular complications, but they are surgically curable if caught early.

In a study of 159 adults investigated for pheochromocytoma (a rare adrenal tumor), 24-hour urinary VMA correctly identified about 63 out of 100 people with the tumor and correctly cleared about 94 out of 100 people without it. A clearly elevated VMA is meaningful, but a normal VMA does not fully rule the tumor out. A separate test called urinary or plasma metanephrines is more sensitive and is now the preferred first-line screen, which is why VMA is often ordered alongside metanephrines rather than alone.

In children with neuroblastoma (a nerve-tissue tumor), urinary VMA combined with a related metabolite (HVA) detects most cases. Adding a broader panel of eight catecholamine breakdown products raises detection to about 95 out of 100. VMA levels also track tumor activity over time and have been used to predict recurrence when combined with serum CA125 and NSE (other tumor markers).

Cardiovascular Stress and Hypertension

Beyond tumors, VMA reflects how hard your sympathetic nervous system is working. After a heart attack, urinary VMA rises sharply and correlates with low blood pressure, heart failure, and dangerous heart rhythms, signaling massive adrenaline release. Many people with essential (no-known-cause) high blood pressure also show urinary VMA above age-matched upper limits, though the elevation appears to be a consequence of the elevated pressure rather than its root cause.

What this means for you: if you have persistent or paroxysmal high blood pressure that resists standard treatment, a VMA test, ideally alongside metanephrines, can help determine whether overactive catecholamine production is part of the picture rather than just garden-variety hypertension.

Environmental and Lifestyle Signals

VMA also moves with environmental exposures. In a cross-sectional study of 696 adults, higher exposure to volatile organic compounds (common indoor air pollutants from solvents, paints, and fuels) was linked to higher urinary VMA, consistent with chronic low-grade sympathetic activation. Exposure to coarse air particles also shifted VMA in a controlled crossover trial. These findings suggest VMA can pick up environmentally driven stress responses that may, over time, contribute to cardiovascular risk.

When Low VMA Is Meaningful

Reduced urinary VMA usually points to dampened sympathetic outflow. In a study of severely obese patients with craniopharyngioma (a tumor that damages the hypothalamus), urinary VMA and HVA were significantly lower than in healthy controls, reflecting blunted sympathetic activity that contributed to reduced physical activity and weight gain. Outside of specific neurological injury, persistently low VMA is uncommon and rarely the reason for testing.

Tracking Your Trend

A single VMA reading captures one snapshot of catecholamine output. Stress hormones swing throughout the day and respond to acute illness, exercise, recent meals, and emotional state. That biological variability is exactly why serial trending matters more than any one number, especially if you are monitoring response to treatment or trying to detect a slow-growing tumor that may not push VMA above the standard upper limit on day one.

A reasonable approach: get a baseline measurement, repeat in 3 to 6 months if you are making lifestyle changes or starting medications that affect sympathetic activity, and then annually if values stay stable. If you are being monitored after surgical removal of a catecholamine-secreting tumor, follow your specialist's schedule, which is typically more frequent in the first year and then at least yearly thereafter.

When Results Can Be Misleading

VMA testing has several well-documented confounders that can produce a misleading single reading. Knowing them protects you from acting on a false alarm or being falsely reassured.

  • Diet in the days before testing: olives have caused falsely high VMA and HVA in a child being monitored for neuroblastoma, briefly mimicking relapse. Lemon intake modestly lowered urinary VMA in 14 healthy volunteers. Diet does not change your underlying biology, only the reading.
  • Acute illness or recent heart attack: urinary VMA rises sharply after a myocardial infarction and during severe physical stress, which can mask or mimic tumor-driven elevations for days to weeks.
  • Recent intense exercise or acute emotional stress: short-term sympathetic activation can briefly push VMA higher without indicating any disease.
  • Ibuprofen: in one laboratory study, ibuprofen metabolites interfered with the chromatography method used to measure urinary HVA and VMA, distorting results in children being tested for neuroblastoma.

What an Out-of-Pattern Result Should Lead You to Do Next

If your VMA comes back clearly elevated, the next step is not panic. It is a targeted workup. The most important companion test is urinary or plasma fractionated metanephrines, which are more sensitive than VMA for pheochromocytoma and paraganglioma. If both are elevated, an endocrinologist will typically arrange imaging of the adrenal glands and along the sympathetic chain to look for a tumor. A mildly elevated VMA with normal metanephrines, no symptoms, and an obvious dietary or stress confounder is usually a cue to repeat the test under cleaner conditions before pursuing further investigation.

If symptoms point strongly toward a catecholamine excess but VMA is normal, do not stop there. A meaningful fraction of catecholamine-secreting tumors can have normal VMA, which is why metanephrines and broader catecholamine panels are now preferred when clinical suspicion is high.

What Moves This Biomarker

Evidence-backed interventions that affect your Vanillylmandelic Acid (VMA) level

Decrease
Surgical removal of a catecholamine-secreting tumor
When the underlying pheochromocytoma or neuroblastoma is removed, urinary VMA falls toward normal because the abnormal source of catecholamine production is eliminated. Persistent or rising VMA after surgery suggests residual or recurrent tumor and is used in combined serum CA125, NSE, and 24-hour urinary VMA models to predict recurrence in children with neuroblastoma.
MedicationStrong Evidence
Increase
Chronic exposure to volatile organic compounds (VOCs) such as solvents, paints, and fuel vapors
In a cross-sectional study of 696 adults, higher exposure to several volatile organic compounds was associated with higher urinary VMA, consistent with chronic sympathetic activation. The researchers interpret this as a biological pathway by which everyday chemical exposures may contribute to cardiometabolic risk over time.
LifestyleModerate Evidence
Increase
Exposure to coarse urban particulate air pollution
In a randomized crossover study of adults, controlled exposure to coarse particulate matter and its biological constituents shifted urinary neural biomarkers including VMA, reflecting systemic stress response and potential effects on the blood-brain barrier.
LifestyleModest Evidence

Frequently Asked Questions

Panels containing Vanillylmandelic Acid (VMA)

Vanillylmandelic Acid (VMA) is included in these pre-built panels.

References

21 studies
  1. Verly IRN, Van Kuilenburg AV, Abeling N, Goorden S, Fiocco M, Vaz F, Van Noesel MM, Zwaan C, Kaspers G, Merks J, Caron H, Tytgat GEuropean Journal of Cancer2017
  2. Amano H, Uchida H, Harada K, Narita a, Fumino S, Yamada Y, Kumano S, Abe M, Ishigaki T, Sakairi M, Shirota C, Tainaka T, Sumida W, Yokota K, Makita S, Karakawa S, Mitani Y, Matsumoto S, Tomioka Y, Muramatsu H, Nishio N, Osawa T, Taguri M, Koh K, Tajiri T, Kato M, Matsumoto K, Takahashi Y, Hinoki aCancer Science2024
  3. Matser Y, Verly IRN, Van Der Ham M, De Sain-van Der Velden MGM, Verhoeven-duif N, Ash S, Cangemi G, Barco S, Popovic M, Van Kuilenburg AV, Tytgat GPediatric Blood and Cancer2023